Package | us.nlm.vsac |
Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1078.935 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1078.935/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.935 |
Version | 20240711 |
Status | active |
Date | 2024-07-11T01:03:01-04:00 |
Name | T2DMMedsBenefittingCKDStage5 |
Title | T2DM meds benefitting CKD stage 5 |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: T2DM meds benefitting CKD, as per ADA 2024 Standards of Care, in stage 5 (or eGFR < 20 mL/min)),(Data Element Scope: RxCUIs for medications containing dulaglutide, liraglutide, and SC semaglutide.),(Inclusion Criteria: Valid RxCUIs),(Exclusion Criteria: Invalidated RxCUIs) |
No resources found
CodeSystem | |
rxnorm | RxNorm |
rxnorm | RxNorm |
ValueSet | |
2.16.840.1.113762.1.4.1078.930 | Dulaglutide meds |
2.16.840.1.113762.1.4.1078.931 | Liraglutide meds |
2.16.840.1.113762.1.4.1078.932 | Semaglutide SC meds |
No narrative content found in resource